Clinical demand for individualized "adaptive" treatment policies in diverse fields has spawned development of clinical trial methodology for their experimental evaluation via multistage designs, building upon methods intended for the analysis of naturalistically observed strategies. Because often there is no need to parametrically smooth multistage trial data (in contrast to observational data for adaptive strategies), it is possible to establish direct connections among different methodological approaches. We show by algebraic proof that the maximum likelihood (ML) and optimal semiparametric (SP) estimators of the population mean of the outcome of a treatment policy and its standard error are equal under certain experimental conditions. This result is used to develop a unified and efficient approach to design and inference for multistage trials of policies that adapt treatment according to discrete responses. We derive a sample size formula expressed in terms of a parametric version of the optimal SP population variance. Nonparametric (sample-based) ML estimation performed well in simulation studies, in terms of achieved power, for scenarios most likely to occur in real studies, even though sample sizes were based on the parametric formula. ML outperformed the SP estimator; differences in achieved power predominately reflected differences in their estimates of the population mean (rather than estimated standard errors). Neither methodology could mitigate the potential for overestimated sample sizes when strong nonlinearity was purposely simulated for certain discrete outcomes; however, such departures from linearity may not be an issue for many clinical contexts that make evaluation of competitive treatment policies meaningful.
INTRODUCTION
Increased interest in individualized treatment policies has shifted the focus of their methodological development from the analysis of "naturalistically" observed strategies (e.g. Murphy and others, 2001) to 2. DESIGN FRAMEWORK AND ESTIMATORS Consider a K-stage trial. For stage k in 1, . . ., K , let S k be the status of the subject measured at the start of the kth stage and A k the treatment assigned by the kth randomization according to values for S k = (S 1 , S 2 , . . ., S k ) and A k−1 = (A 1 , A 2 , . . ., A k−1 ), with A 1 a function of S 1 . SMAR assignment to treatment options can be expressed in terms of (sequential) allocation to different decision rules, which determine treatment as a function of treatment and response history. We write a k = d k (S k = s k , A k−1 = a k−1 ) for the decision rule d k at the kth stage, where a k and s k denote values for treatment and state; the randomization probabilities for d k , denoted { p k (d k |S k ,A k−1 )}, are known and experimentally fixed functions of prior state-treatment history. The strategies to be evaluated can be represented as sequences of the decision rules with positive probability of assignment. Each sequence d = {d 1 , d 2 , . . ., d K } corresponds to an ATS if the domain for each successive rule includes the state-treatment histories produced by previous rules in the sequence. This condition ensures that the K -stage ATS is a well-defined policy for adaptively determining the "next" treatment. The introductory example consists of two decision rules {d 1 , d 2 }: A = d 1 (S 1 = 1), A + C = d 1 (S 1 = 2) and B = d 1 (S 1 = 3), where the S 1 indicates response to A. The second decision rule is similarly defined, e.g. a 1 = d 2 (S 2 = 1, a 1 ), where S 2 indicates response measured after a 1 = d 1 (S 1 ).
The SMAR design includes a primary outcome Y for evaluation purposes, obtained after the K th stage of randomization. We judge the performance of an ATS d byμ d , the population mean of Y that would be observed if all subjects were treated according to d.
Estimator of the mean of an ATS
When the observed allocation of subjects matches that intended by design, the MOM estimator of μ d is equal to the SP marginal mean (MM) estimator defined by Murphy for SMAR trials (Lavori and Dawson, 2007) . This condition, which occurs asymptotically and might be achieved in a study using sequentially blocked randomization, is needed because the MM estimator is defined in terms of randomization probabilities rather than their sample counterparts. In this case, both estimators of μ d can be expressed as:
where m K (s K ) is the sample mean of final responses among subjects sequentially randomized to d through K and having state values S K = s K , and f k (s k ) is the sample (conditional) response rate for S k = s k , given assignment to d through k−1 and S k−1 = s k−1 . The estimator (2.1) is a version of the nonparametric G-computational formula and is suitable for strategies that adapt treatment according to discrete states, such as the ATS in Section 1. Murphy (2005) , building upon the work of Murphy and others (2001) for observational data, presented an "optimal" SP estimator of μ d for use in SMAR trials, which has the smallest variance among the class of all regular asymptotically linear estimators. Let D k = k j=1 I (A j = d j (S j , A j−1 )) and P k (s k ) = k j=1 p j (d j |S j , A j−1 ). The optimal estimator is the solution to the efficient estimating equation 1 n U opt = 0, where n is the number of subjects and U opt is
for k in 1, . . . , K ; Y d denotes the primary outcome when the subject is treated according to strategy d. For k = 1, μ k (s k , d k−1 ) ≡ μ 1 (s 1 ). The G-computational formula (2.1) can be used to provide consistent nonparametric estimates of the μ k (given SMAR), in which case, the solution to the estimated estimating equation is optimal (most efficient) (Murphy and others, 2001) . With some calculation, the optimal estimator also reduces to (2.1), a result that holds even if the observed assignment proportions differ from the preset probabilities (despite U opt being defined in terms of randomization probabilities).
Because the ML estimates for means and proportions coincide with the plug-in estimates obtained by the MOM for common distributions of interest here, (2.1) is also ML. It is also equal to the predictive estimator of μ d , assuming noninformative priors (Dawson and Lavori, 2008) . We therefore refer to (2.1) unambiguously as the estimator of the ATS mean, denotedμ d .
Variance estimators of the estimator of the mean of an ATS
To obtain the ML variance ofμ d , we assume that (i) the final outcome Y has a stratified normal (continuous case) or Bernoulli (discrete case) distribution across strata indexed by the possible sequences (s K , a K ); (ii) the intermediate states S k are distributed conditionally, given (s k−1 , a k−1 ), as multinomial random variables; (iii) model parameters are distinct across state-treatment histories for a given stage k and across stages (reflective of SMAR allocation). Because the sequence of nested randomizations in a SMAR trial gives rise to a monotone pattern of missingness for each ATS, the likelihood for the parameters in (i) and (ii) can be factored into components, each of which is a complete-data problem; standard theory dictates that the information matrix and hence (asymptotic) ML covariance matrix of the parameters is block diagonal, with each block corresponding to a complete-data component (Little and Rubin, 1987) . It is possible to obtain the ML variance ofμ d from the block-diagonal covariance matrix (once calculated); however, a more tractable derivation uses iterated variance decomposition (Little and Rubin, 1987) . The application to the SMAR set up factors the term of (2.1) for s K 
. ., K . The iterated calculation produces the same estimator obtained using probability calculus coupled with MOM (Lavori and Dawson, 2007) or Bayesian predictive inference (Dawson and Lavori, 2008) . We usev ML to denote the variance estimator ofμ d provided by these three derivations.
Iterated variance decomposition yields thatv ML =v n +v p ;v n is the "naïve" variance estimate that assumes the coefficients of m K (s K ) in (2.1) are known a priori, andv p is the "penalty" paid for estimating them:v and Lavori, 2008) . The côv(φ K , φ K ) can be obtained by induction on k, with K = 1 being the usual multinomial calculation (Lavori and Dawson, 2007) . For general K ,v p decomposes into stage-specific components of penalty variance, with the kth-stage term of côv(φ K , φ K ) reducible up to multiplicative factors to côv( f k , f k ). See Appendix A in the supplementary materials available at Biostatistics online. The estimated asymptotic variance of the optimal SP estimator of μ d , denotedv OPT , is obtained nonparametrically from the variance of U opt (Murphy, 2005) . Specifically,v OPT is the estimate of 1
(2.4) and the expectation E d () is calculated under the distribution of S K and Y when all treatments are assigned according to the strategy d. As before, the μ k are estimated using the G-computational formula, which guarantees thatv OPT achieves the SP efficiency bound. In Appendix A in the supplementary materials available at Biostatistics online, we use induction to algebraically show equality of the variance estimators. The result holds asymptotically without restriction, but for finite samples requires that the observed allocation of subjects matches that intended by design, as set out in Section 2.1 for the MM estimator of μ d . For analytic derivations, we assume blocking or some other form of constrained randomization makes this distinction moot and use the notation p k (d k |S k , A k−1 ) interchangeably for expected and observed proportions under d.
A key element of the inductive proof is the ANOVA decomposition:
Algebraic reexpression of (m K −μ k ) 2 in (2.5) in terms of covariances of the "pseudo" proportions p = K j=k f j , p = K j=k f j provides a direct comparison ofv OPT −v n to the penalty component of v ML in (2.3). Because the kth-stage term ofv p restricts covariance uncertainty to f k and f k (see above), the differencev OPT −v ML gives rise to K remainder terms that telescope to zero (proved inductively). We remark that the variance components of V (U opt ), and consequently ofv OPT , are expressed in terms of squared deviations, a property that must be shared byv ML for equality to hold. This motivates (i) as the likelihood model in Y . Murphy (2005) obtains the simple MM (SP) estimator of μ d and its standard error by setting each μ k in U opt to μ d . To characterize the potential loss of efficiency in doing so, we expressv MM as:
SP EFFICIENCY GAINS WITH THE OPTIMAL ESTIMATOR
for comparison to the ANOVA decomposition (2.5) ofv OPT ;v b accounts for response heterogeneity across subgroups indexed by state history (Lavori and Dawson, 2007) . With some algebra, it follows from (2.6)
is the number of subjects sequentially randomized to d through K and having state history
which can be reexpressed as 
for all k. The case K = 3 suffices to concretely explicate the general result:
( 3.3)
The SMAR randomization probabilities specified by the trialist govern SP efficiency gains withv OPT in a simple way under the assumed restrictions. The strength of the relationship of state history to Y , as evidenced by the magnitudes of the δ k , has impact as well, consistent with simulated results for two-stage trials (Wahed and Tsiatis, 2004) . Differentiation of (3.3) shows that efficiency is maximized when each S k acts like a flip of a fair coin, thereby allowing sequential allocation of subjects to each possible state history. The worst improvement occurs when S k is a degenerate binomial (all mass on one outcome) at each stage but the last. But then the study is not adaptive before the last stage and is equivalent to the cross-sectional K = 1 case.
OPTIMAL SP VARIANCE FOR SAMPLE SIZE CALCULATIONS
We develop sample size formulae for inference for μ d under the assumption that expected and observed SMAR allocations coincide and choose to use the SP variance estimator forμ d because of its marginal formulation. We further assume that
in order to reexpress V (U ) opt in terms of familiar regression quantities. Applying iterated expectation to the kth-stage term in (2.4) gives
if the kth-stage randomization probabilities are all equal to p k (d k ), as would occur in a "balanced' SMAR trial. In this case,
be the coefficient of determination for the regression of Y d on S d,K , and R 2 k denote the (population) increment in coefficient of determination when S d,k is added to the regression of Y d on S d,k−1 . Then V (U opt ) becomes
noting that R 2 T = R 2 k . We refer to the multiplier of σ 2 Y as the "variance inflation factor" (VIF) due to the SMAR design, which generalizes to
when randomization probabilities depend on prior state values. Using either (4.1) or (4.2) as appropriate provides the SMAR version of the usual one-sample t-test formula for sample size: (z α/2 +z β ) 2 VIF ES 2 , where α is the significance level, 1 − β is the power to be achieved, and ES = (μ d −μ 0 )/σ Y is the standardized difference between μ d and the null meanμ 0 .
For a balanced SMAR trial in which p k (d k |S k , A k−1 ) ≡ p k (d k ) for all k, the sample size formula only requires that the unknown distribution of (S d,K , Y ) be restricted in terms of the V d (Y |s d,k ) , assumed homogenous across state values S d,k = s d,k . Homogeneity of variance is a simplifying assumption typical of power calculations for fixed treatment trials, but sequential allocation makes the assumption unlikely for allK stages. More subtly, the assumed equality of the V d (Y |s d,k ) algebraically transforms the stratified (nonparametric) regression structure of V (U opt ) resulting from optimal SP theory into linear association, as characterized by the R 2 k in the VIF. Although the requirement of homogenous variances does not directly restrict conditional expectations, (4.1) or (4.2) may only partially account for any nonlinearity in the E d (Y |s d,k ) .
We remark that our sample size formulae are conditional on the SMAR allocation and hence may underestimate the required number of subjects; calculations based on (4.1) suggest that the typical impact of such conditioning will be negligible when constrained randomization is used.
SIMULATION STUDIES
A central issue to the performance of the sample size formula in Section 4 is how well the parametric reexpression of V (U opt ), derived assuming homogeneity of variance, reflects the nonparametric inference carried out using the estimators in Section 2. It may be that successive stratification leads to one or more random zeroes at intermediate stages of randomization, even if the nominal level of power is achieved (in the frequency sense). As the sample size grows, the chance of this diminishes. We conducted simulations to understand the degree to which good performance of the sample size formula across repeated samples protects the trialist from an unlucky (nonreplete) SMAR realization. Because the formula may also fail to protect against near sampling zeroes (and thereby interfere with constrained randomization), we calculated the test statistic twice, using ML and SP estimators.
The simulation set up is structured to explicate the relationship between "repleteness," defined as the lack of random zeroes at any intermediate stage of the SMAR experiment, and calculated sample size. Data for the ATS in the Introduction, denoted as d, are generated by the following scheme. The state space for symptom severity at each stage is {1,2,3}; these values determine whether to adaptively continue, augment or switch medication, using the stage-specific options specified by d. As in the STAR*D antidepressant study, S d,1 ≡ S 1 is obtained after an initial trial on the medication A; baseline values are equiprobable. The values for S d,2 evolve according to the transition matrix (TM) with rows (0.7, 0.2, 0.1), (0.5, 0.3, 0.2), (0.1, 0.5, 0.4), where TM i j = Pr( j|i), consistent with "healthier" subjects having greater probability of better successive outcomes. The final outcome is generated as a regression on state history. For the continuous case, Y d = S T d,2 β + e, e ∼ N (0, σ 2 e ), where (β 1 , β 2 ) = (1, 2) and the intercept β 0 = 0.5 is the coefficient for S 0 ≡ 1. For the discrete case, Y d is Bernoulli with probability p = logit −1 (S T d,2 β), (β 1 , β 2 ) = (1, 2); β 0 is −6.0, −4.5, or −3.0 to govern the degree of nonlinearity in expected Bernoulli outcomes.
The simulation set up is further structured to investigate SP efficiency gains (relative to the MM estimator) beyond the case of a balanced design required by the analytic derivations in Section 3. In the simulations, random assignment to d depends on prior state values in the following way: subjects who are (well, in partial remission, ill) continue on d with probability (1, 1/3, 1/2); accordingly, we use formula (4.2) to calculate sample sizes. Sequential blocking is used throughout to ensure whenever possible that observed and expected allocations agree; constrained randomization also protects against nonrepleteness. Additionally, simulated trials vary by whether they use a "safe" mechanism to guarantee positive sample sizes across state histories at both stages of the trial (Lavori and Dawson, 2007) . Specifically, safe implies that once the number of subjects for a particular state history falls below a certain value (set here to 6), further randomization stops and subjects with those states continue on d thereafter. The safe mechanism is intended to reflect the effects of good practice in the sense that the trialist would ensure repleteness either through design or by monitoring subject accrual during the trial.
For purposes of inference for μ d , we set the standardized effect size in the sample size formula to be either 0.2 or 0.4. The trialist might specify the larger ES value to ensure adequate precision for individual ATS means when planning a pilot SMAR trial. The inherent "cost" in successfully implementing a whole-treatment strategy makes it unlikely that the trialist would find effects smaller than 0.2 of practical relevance. Table 1 summarizes 2000 replications of the set up for continuous Y d for every combination of ES = 0.2, 0.4 and σ e = 0.5, 1, 2. Throughout, the nominal level of power to be achieved was set to 0.80, with the level of the test = 0.05. The test statistic (the difference of the estimated mean and the null value divided by the standard error) was compared to 1.96, suggested by asymptotic normality of the ML and SP estimators of μ d .
RESULTS
The results show that when ES = 0.2, the calculated sample sizes ensure repleteness for almost all experiments. By contrast, when ES = 0.40, the proportion of replete experiments among the 2000 replications ranges from 60% to 89%. One could argue that for most SMAR trials, the primary interest will be to detect moderate-sized causal effects, thereby increasing the sample size beyond that provided by the generalized t-test formula in Section 4 when ES = 0.4. Nonetheless, the simulations serve to illustrate the relevance of repleteness to good planning of a SMAR experiment, beyond the usual sample size considerations.
A more striking result in Table 1 are the differences in power achieved by the ML and optimal SP estimators. ML estimation is mostly robust to even substantial failures of repleteness, because of its use of sample quantities in (2.1) and (2.3) based on allocated proportions. In contrast, the SP reliance on assignment probabilities precludes the optimal estimator (and its standard error) from tuning to the sample at hand. This is true even with mostly replete repetitions, highlighting the influence of near sampling zeroes on achieved power with SP estimation. The expansion of Table 1 in Appendix B in the supplementary materials available at Biostatistics online shows that differences in power for the two approaches are influenced much more by their differences in estimates of μ d than by differences in estimated standard errors. The cases n = 320, 404 show this to be true for even modest loss of power when sample sizes for some strata are too small for sequentially blocked randomization to achieve a priori assignment probabilities. We note that the efficiency gains for ML estimation are modest, with relative efficiency running from 0.95 to 1.0, for simulated trials without safe turned on but using constrained randomization.
It is not surprising that the optimal estimator may sometimes be underpowered when the simulated trials use the safe option, given that certain a priori randomization probabilities may be set to zero. In contrast, ML estimation ensures nominal power in these cases, albeit conservatively for some scenarios. This property suggests that ML estimation is a suitable choice for inference, prior to the execution of the trial and any knowledge of the stochastic process underlying intermediate states. More generally, its "self-tuning" property of in the face of random and near sampling zeroes reminds us that the asymptotic ML variance estimator coincides with the finite sample one obtained from the MOM. Table 2 shows that repleteness and near sampling zeroes have at most moderate impact on the SP efficiency gains provided by the optimal estimator; such impact occurs because of the (inversely weighted) estimates of theμ k in U opt . In theory, efficiency gains for fixed σ e should not depend on n, and simulations with excessively large sample sizes show this to be the case. For the realistic values of n in Table 2 , the relative efficiency for any given value of σ e depends on whether the sample size was geared to ES = 0.2 or ES = 0.4. Nonetheless, the results of the simulations confirm that the strength of the relationship of state history to Y d , as evidenced by the R 2 T values, governs the magnitude of efficiency gains. Table 3 for the binary set up shows the sample size formula provides close to the nominal power of 0.80, albeit smaller at times, for at most moderate nonlinearity in expected Bernoulli outcomes (β 0 = −6.0, −4.5), and is conservative otherwise. We attribute the excessive sample sizes for the case β 0 = −3.0 to the inability of the VIF to adequately account for strong nonlinearity rather than due to marked failure of sequential homogeneity of variance, given good performance for the normal model set up in the presence of this type of failure (Dawson and Lavori, 2010) . However, strong departures from linearity may not be of issue for many realistic applications because of the impact on μ d , which is much higher for β 0 = −3.0: μ d = 0.82 compared to μ d = 0.44, 0.63 for β 0 = −6.0, −4.5, respectively. ATS will tend to be moderately successful (or not) in populations with sufficient response heterogeneity to make sequential treatment adaptation clinically attractive, making values of μ d such as 0.82 unlikely to occur.
The performance of SP and ML estimation is more similar for the binary case than for continuous Y d , although larger sample sizes (expected for discrete outcomes) promote significant differences in achieved power. The impact on achieved power due to differences in estimates of μ d is sometimes canceled out by the impact due to differences in estimated standard errors. When repleteness held across replications, differences in standard error had modest impact. See Appendix B in the supplementary materials available at Biostatistics online. 
DISCUSSION
Prior development of SMAR sample size formulae derived from SP theory have specified estimators that used the known randomization probabilities (Murphy, 2005; Feng and Wahed, 2009 ) and did not use the most efficient influence function as a basis for the derivations. Building upon that work, we have developed theoretical connections that not only provide a more efficient basis for sample size calculations but also help to establish the advantage of using observed (ML) rather than expected (optimal SP) allocations for planned evaluation of ATS. The better performance of ML estimation in terms of achieved power parallels the superiority of model-based weights for studies with nonrandomized treatments (less bias) or missing data (better efficiency) (see, e.g. Rotnitzky and Robins, 1995) . We note that the results obtained here may be specific to the sequential context in which randomizations are adaptively nested over time.
The sample and population formulations of SP variance in this paper elucidate the central role played by response heterogeneity in determining the magnitude of sequential uncertainty. Section 3 offers a nonparametric characterization of sample response heterogeneity in terms of stage-specific between-subgroup sum of squares, which captures the sequential effect of response heterogeneity on SP efficiency. The increments in regression-based coefficients of determination defined in Section 4 provide the parametric counterparts at the population level and describe the sequential effect of response heterogeneity on sample size requirements. Less apparent is the intrinsic role of response heterogeneity to estimators developed for SMAR data. The entire premise of an ATS relies on a strong relationship between outcome and state on which to base decisions. Because the SMAR design mimics sequential decision making, the missingness intentionally created by sequential (nested) randomization is governed implicitly by variation in responses across states for any given strategy. In the absence of such variation, treatment assignment at any given stage reduces to a flip of a fair coin, making sequential adjustment for state history unnecessary. For certain estimators, such as the ML and optimal SP ones considered here, their adjustment for SMAR missingness to guarantee consistency also reaps the usual efficiency gains, as translated to the sequential context.
The sample size formulae we developed apply directly to inference for a single ATS but require extension for paired comparisons. In Dawson and Lavori (2010) , we use the ML formulation of variance to derive an analytic approximation to (positive) between-strategy covariance created by sequential nested randomization and adjust sample sizes for pairwise comparisons accordingly. The adjusted sample size
